Siqueira MG, Tavares PL, Martins RS, Heise CO, Foroni LHL, Bordalo M, et al
In this way, we only included new SGLT-2i or GLP-1RA users with obesity when initiating therapy, in order to produce groups as similar as possible at baseline
Patients should contact their healthcare provider if they experience severe or persistent side effects, signs of hypoglycaemia (particularly if taking insulin or sulfonylureas), symptoms of pancreatitis (severe abdominal pain), or if there is no improvement in blood glucose control after 6 months of treatment at the maximum tolerated dose
But if that were true, shed promote foods that activate the GLP-1 hormone, like whole grains, fruits, vegetables, and lean proteins
Their defined composition and consistency make them suitable for repeatable experimental frameworks
Data sourced from pooled SURPASS-1 to SURPASS-5 trials (Patel et al., Diabetes Obes Metab 2024)